Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Prabakar Rao

Retina Specialist Saint Louis, MO Medical Doctor

NPI 1417959115 CMS profile 688771

4901 Forest Park Ave, Dept Ophthalmology, 6Th Fl, Saint Louis, MO 63108

Open in the dashboard

General payments

$32

1 record reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prabakar Rao of Saint Louis, MO is reported in the CMS Open Payments database as having received $32 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 1st percentile of Retina Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $32 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prabakar Rao
  • Retina Specialist median
  • Middle half of Retina Specialist
  • National median

In program year 2025, general payments to Prabakar Rao were reported at $32. Among 1,235 Retina Specialist profiles paid that year, the median was $457 and the middle half received between $175 and $1,079.

Show as a table
Year Prabakar Rao Retina Specialist median Middle half National median
2019 $0 $410 $157–$1,517 $163
2020 $0 $168 $65–$778 $114
2021 $0 $258 $101–$1,161 $132
2022 $0 $418 $162–$1,488 $149
2023 $0 $476 $178–$1,312 $160
2024 $0 $520 $188–$1,372 $164
2025 $32 $457 $175–$1,079 $169

Breakdown

Who paid General payments · program year 2025
  1. Smith+Nephew, Inc. $32 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $32 1 payment
Products named General payments · program year 2025
  1. GRAFIX PL $32 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

564

Median for Ophthalmology: 891

Drug cost

$34,001

Median for Ophthalmology: $68,233

Branded share of claims

8.5%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Difluprednate Generic 64 $11,361
Prednisolone Acetate Generic 226 $7,535
Durezol Difluprednate Brand 11 $4,788
Valganciclovir Hcl Generic 13 $3,946
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 13 $2,102
Brimonidine Tartrate Generic 24 $1,394
Valacyclovir Valacyclovir Hcl Brand 11 $1,356
Timolol Maleate Generic 47 $396
Tobramycin Generic 78 $320
Dorzolamide Hcl Generic 20 $299

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$524,269

Of which drugs: $362,678

Medicare patients

437

Average age 73

Services billed

7,315

250 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 47%
Diabetes 36%
Chronic kidney disease 28%
Ischemic heart disease 24%
Depression 18%
Heart failure 16%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 49 338 $221,781
Injection, faricimab-svoa, 0.1 mg J2777 Office 15 4,500 $123,796

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Retina Specialist in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record